Mother-to-child Transmission of HBV in China

NCT ID: NCT05172453

Last Updated: 2021-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to evaluate the feasibility of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030, a multi-center, prospective cohorts study was conducted to investigate MTCT of HBV in China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, multicenter study of pregnant women with HBV infection was conducted from July 2015 up to now in a real world setting in the Shield Project stage Ⅱ. Inclusion criteria was any pregnant women with chronic HBV infection. Pregnant women were excluded if they had a positive serologic test for human immunodeficiency virus or hepatitis C virus or any co-morbidity that might reduce compliance or if they were unable or unwilling to use the mobile health application-Shield APP. Enrolled mothers and infants were prospectively followed until infant post-vaccination serologic testing (PVST) was performed at 7-12 months of age.

Demographic data, antiviral treatment history, pregnancy and labour history, co-morbidity, HBV serologic marker tests, HBV DNA tests, liver function tests, mode of delivery, neonatal characteristics (height, weight, head circumference, Apgar score and any major birth defect), breastfeeding and PVST for infants at 7-12 months of age were collected.

A mobile health application called "SHIELD" was developed and used in the Shield Project stage Ⅱ to collect data and provide support for communication between mothers and their doctors. All laboratory test reports, questionnaires and other relevant information was uploaded into SHIELD. Participants could consult with their doctors via SHIELD during the follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B, Chronic Mother to Child Transmission

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hepatitis B mother-to-child transmission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nationwide hospital-based cohort

HBV-infected mother-infant pairs have been followed from registry to post vaccination serological test (PVST) in hospitals nationwide.

comprehensive management algorithm for preventing mother-to-child transmission of HBV

Intervention Type OTHER

To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the "Management algorithm for prevention of mother-to-child transmission of hepatitis B virus" based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents.

Community-based cohort

HBV-infected mother-infant pairs have been followed from registry to post vaccination serological test (PVST) in Bao' an district, Shenzhen

comprehensive management algorithm for preventing mother-to-child transmission of HBV

Intervention Type OTHER

To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the "Management algorithm for prevention of mother-to-child transmission of hepatitis B virus" based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

comprehensive management algorithm for preventing mother-to-child transmission of HBV

To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the "Management algorithm for prevention of mother-to-child transmission of hepatitis B virus" based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women with chronic HBV infection.

Exclusion Criteria

* positive serologic test for human immunodeficiency virus or hepatitis C virus;
* any co-morbidity that might reduce compliance;
* unable or unwilling to use the mobile health application-Shield APP
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Foundation for Hepatitis Prevention and Control

UNKNOWN

Sponsor Role collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

Sponsor Role collaborator

Nanfang Hospital, Southern Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jinlin Hou

Professor & Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jinlin Hou

Role: PRINCIPAL_INVESTIGATOR

Nanfang Hospital, Southern Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jinlin Hou

Guangzhou, Guangdong, China

Site Status RECRUITING

302 military hospital of China

Beijing, , China

Site Status RECRUITING

Beijing YouAn Hospital, Capital Medical University

Beijing, , China

Site Status RECRUITING

The First Affiliated Hospital of Jilin University

Changchun, , China

Site Status RECRUITING

The First People's Hospital of Foshan

Foshan, , China

Site Status RECRUITING

Fifth Affiliated Hospital of Southern Medical University

Guangzhou, , China

Site Status RECRUITING

Guangdong Maternal and Child Care Hospital

Guangzhou, , China

Site Status RECRUITING

Guangzhou No. 8 People's Hospital

Guangzhou, , China

Site Status RECRUITING

Zhujiang Hospital, Southern Medical University

Guangzhou, , China

Site Status RECRUITING

Xixi Hospital of Hangzhou

Hangzhou, , China

Site Status RECRUITING

Third Hospital of Jiujiang

Jiujiang, , China

Site Status RECRUITING

Second Hospital of Nanjing

Nanjing, , China

Site Status RECRUITING

Shanghai Public Health Clinical Center

Shanghai, , China

Site Status RECRUITING

Shenzhen Baoan Maternal and Child Care Hospital

Shenzhen, , China

Site Status RECRUITING

The Third People's Hospital of Shenzhen

Shenzhen, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jinlin Hou

Role: CONTACT

Phone: +86 13802727354

Email: [email protected]

Zhihua Liu

Role: CONTACT

Phone: +8618665000386

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jinlin Hou

Role: primary

Zhihua Liu

Role: backup

Mei Wang

Role: primary

Hua Zhang

Role: primary

Jing Jiang

Role: primary

Honglian Bai

Role: primary

Qing Shan

Role: primary

Jianhong Xia

Role: primary

Huiyuan Liu

Role: primary

Xiaozhu Zhong

Role: primary

Chun Zhao

Role: primary

Guojun Shen

Role: primary

Guorong Han

Role: primary

Li Yan

Role: primary

Wei Wang

Role: primary

Yingxia Liu

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

shield project 02

Identifier Type: -

Identifier Source: org_study_id